Cytek Historical Balance Sheet
| CTKB Stock | USD 5.29 0.23 4.55% |
Trend analysis of Cytek Biosciences balance sheet accounts such as Other Current Liab of 18.5 M, Total Current Liabilities of 40.7 M or Total Stockholder Equity of 256.8 M provides information on Cytek Biosciences' total assets, liabilities, and equity, which is the actual value of Cytek Biosciences to its prevalent stockholders. By breaking down trends over time using Cytek Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Cytek Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cytek Biosciences is a good buy for the upcoming year.
Cytek Biosciences Inventory |
|
Cytek |
About Cytek Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Cytek Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Cytek Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cytek Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cytek currently owns. An asset can also be divided into two categories, current and non-current.
Cytek Biosciences Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Cytek Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cytek Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Cytek Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cytek Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from Cytek Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cytek Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.At present, Cytek Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Property Plant And Equipment Net is expected to grow to about 30.7 M, whereas Total Assets are forecasted to decline to about 389.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 6.8M | 27.7M | 24.9M | 18.5M | Total Assets | 463.7M | 519.5M | 497.7M | 389.7M |
Cytek Biosciences balance sheet Correlations
Click cells to compare fundamentals
Cytek Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Cytek Stock
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.14) | Revenue Per Share 1.486 | Quarterly Revenue Growth (0.06) | Return On Assets (0.03) |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.